GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (FRA:MB8) » Definitions » Cyclically Adjusted Price-to-FCF

Moberg Pharma AB (FRA:MB8) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Moberg Pharma AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Moberg Pharma AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Moberg Pharma AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Cyclically Adjusted Price-to-FCF Chart

Moberg Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Moberg Pharma AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Moberg Pharma AB's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Moberg Pharma AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Moberg Pharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Moberg Pharma AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.046/132.8245*132.8245
=-0.046

Current CPI (Mar. 2025) = 132.8245.

Moberg Pharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -0.308 99.950 -0.409
201506 -0.596 99.995 -0.792
201509 0.409 100.228 0.542
201512 -0.064 100.276 -0.085
201603 -0.325 100.751 -0.428
201606 0.056 101.019 0.074
201609 -14.651 101.138 -19.241
201612 -15.709 102.022 -20.452
201703 -0.399 102.022 -0.519
201706 -1.262 102.752 -1.631
201709 1.794 103.279 2.307
201712 0.961 103.793 1.230
201803 -0.572 103.962 -0.731
201806 0.612 104.875 0.775
201809 -0.074 105.679 -0.093
201812 -0.280 105.912 -0.351
201903 0.200 105.886 0.251
201906 -2.608 106.742 -3.245
201909 -1.362 107.214 -1.687
202003 -0.394 106.563 -0.491
202006 -0.669 107.498 -0.827
202009 -0.481 107.635 -0.594
202012 -0.512 108.296 -0.628
202103 -0.292 108.360 -0.358
202106 -0.128 108.928 -0.156
202109 -0.176 110.338 -0.212
202112 -0.102 112.486 -0.120
202203 -0.400 114.825 -0.463
202206 -0.215 118.384 -0.241
202209 -0.156 122.296 -0.169
202212 -0.156 126.365 -0.164
202303 -0.351 127.042 -0.367
202306 -0.257 129.407 -0.264
202309 -0.110 130.224 -0.112
202312 -0.076 131.912 -0.077
202403 -0.040 132.205 -0.040
202406 -0.076 132.716 -0.076
202409 -0.049 132.304 -0.049
202412 -0.028 132.987 -0.028
202503 -0.046 132.825 -0.046

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Moberg Pharma AB  (FRA:MB8) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Moberg Pharma AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB Business Description

Industry
Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

Moberg Pharma AB Headlines

No Headlines